Effect of PF-00734200 in Subjects With Type 2 Diabetes

Phase 2CompletedNCT00618007

Pfizer289 enrolled

Overview

To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

289

Conditions

Diabetes Mellitus, Type 2

Interventions

PF-00734200 30 mg QDDRUG

30 mg QD

PF-00734200 20 mg QDDRUG

20 mg QD

PlaceboDRUG

Placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Men or women between 18-80 years of age with poorly controlled Type 2 diabetes Exclusion Criteria: Type 1 or secondary forms of diabetes Currently using insulin

Locations (79)

Outcomes

Primary Outcomes

HbA1c

Time frame: 12 weeks

Secondary Outcomes

Fasting Glucose

Time frame: 12 weeks

Fasting Insulin

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Chandler, Arizona, United States

Pfizer Investigational Site

Litchfield Park, Arizona, United States

Pfizer Investigational Site

Phoenix, Arizona, United States

Pfizer Investigational Site

Artesia, California, United States

Pfizer Investigational Site

Cerritos, California, United States

Pfizer Investigational Site

Fresno, California, United States

Pfizer Investigational Site

Greenbrea, California, United States

Pfizer Investigational Site

Huntington Beach, California, United States

Pfizer Investigational Site

Los Angeles, California, United States

...and 69 more locations